...
首页> 外文期刊>Radiation oncology >Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic
【24h】

Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic

机译:梅奥诊所治疗性意图再照射治疗局部局部复发或新发头颈部鳞状细胞癌患者的结果

获取原文
           

摘要

Background We reviewed outcomes of patients with loco-regionally recurrent (LRR) or new primary (NP) squamous cell carcinoma of the head and neck (SCCHN) treated at our institution with reirradiation (RRT). Methods Patients received definitive RRT (DRRT) or post-operative RRT following salvage surgery (PRRT) from 2003 to 2011. Measured survival outcomes included loco-regional relapse free survival (LRFS) and overall survival (OS). Results Among 81 patients (PRRT, 42; DRRT, 39), median PRRT and DRRT doses were 60?Gy (12–70?Gy) and 69.6?Gy (48–76.8?Gy). The majority of patients received IMRT-based RRT ( n =?77, 95?%). With median follow-up of 78.1?months (95?% CI, 56–96.8?months), 2-year OS was 53?% with PRRT and 48?% with DRRT ( p =?0.12); 23?% of patients were alive at last follow-up. LRFS at 2?years was 60?%, and did not differ significantly between PRRT and DRRT groups. A trend toward inferior LRFS was noted among patients receiving chemotherapy with RRT versus RRT alone ( p =?0.06). Late serious toxicities were uncommon, including osteoradionecrosis (2 patients) and carotid artery bleeding (1 patient, non-fatal). Conclusions OS of PRRT- and DRRT-treated patients in this series appears superior to the published literature. We used IMRT for the majority of patients, in contrast to several series and trials previously reported, which may account in part for this difference. Future studies should seek to improve outcomes among patients with LRR/NP SCCHN via alternative therapeutic modalities such as proton radiotherapy and by incorporating novel systemic agents.
机译:背景我们回顾了在我院接受再放射治疗(RRT)的局部复发(LRR)或新发的原发性(NP)头颈部鳞状细胞癌(SCCHN)患者的结局。方法2003年至2011年,患者接受挽救性手术后的确定性RRT(DRRT)或术后RRT(PRRT)。测得的生存结局包括局部无复发生存(LRFS)和总体生存(OS)。结果在81例患者(PRRT,42; DRRT,39)中,PRRT和DRRT的中位剂量分别为60?Gy(12–70?Gy)和69.6?Gy(48-76.8?Gy)。大多数患者接受了基于IMRT的RRT(n =?77,95?%)。中位随访时间为78.1个月(95%CI,56-96.8个月),PRRT和DRRT的2年OS分别为53%和48%(p =?0.12)。在最后一次随访中,有23%的患者还活着。 LRFS在2年时为60%,PRRT和DRRT组之间无显着差异。在接受RRT化疗的患者与仅接受RRT化疗的患者中,LRFS趋于劣势(p =?0.06)。晚期严重毒性反应不常见,包括骨放射性坏死(2例)和颈动脉出血(1例,非致命性)。结论该系列的PRRT和DRRT治疗的患者的OS似乎优于已发表的文献。与先前报道的多个系列和试验相反,我们对大多数患者使用了IMRT,这可能部分解释了这种差异。未来的研究应寻求通过替代治疗方式(如质子放射疗法)和纳入新型全身性药物来改善LRR / NP SCCHN患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号